Vaccitech’s VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses

Read full release

Vaccitech Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

Read full release

Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus

Read full release

Vaccitech Oncology Limited’s ChAdOx1/MVA prime-boost immunotherapeutic shows preclinical potential as a novel cancer treatment

Read full release

Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection

Read full release